IgA subclass switch recombination in human mucosal and systemic immune compartments

Human immunoglobulin A (IgA) comprises two IgA subclasses, IgA1 and IgA2, whose distribution has been shown by immunohistochemistry to be different in various body compartments. In comparison with systemic immune compartments, we investigated the IgA switch profiles at the molecular level in salivary and lacrimal glands, nasal mucosa, and proximal and distal gut mucosa. Direct switching from IgM to IgA1 or IgA2 predominated in all immune compartments analyzed. Similar composition of the Sμ-Sα1 and Sμ-Sα2 junctions was observed, including microhomology usage, which suggested that there is no major difference in the actual recombination mechanism utilized during IgA subclass switching. The proportion of IgA1/IgA2 switch recombination events largely paralleled the previously published immunohistochemical representation of IgA1(+) and IgA2(+) plasma cells, implying that the local subclass distribution generally reflects precommitted memory/effector B cells that have undergone IgA subclass switching before extravasation at the effector site. The extremely low or undetectable levels of activation-induced cytidine deaminase (AID) and Iα-Cμ circle transcripts in intestinal lamina propria samples as compared with Peyer's patches suggest that the cellular IgA subclass distribution outside of organized gut-associated lymphoid tissue is only to a minor extent, if at all, influenced by in situ switching.

Diagnostic value of cytological and microbiological methods in cryptococcal meningitis

The aim of this study was to investigate diagnostic methods for cryptococcal meningitis (CM). A retrospective analysis was conducted for 31 patients with CM confirmed by etiologic detection of cerebrospinal fluid in our hospital in the past 5 years. Nineteen cases in 31 patients were confirmed with CM in the first diagnosis, with a misdiagnosis rate of 38.7%. The positive rates of cryptococcus detection in cerebrospinal fluid with May-Grünwald-Giemsa (MGG)-, ink-, and Alcian blue-staining methods were 86.9, 70.9, and 80.6%, respectively. The misdiagnosis rate of CM is high during the early stage of disease. The total positive rate of cryptococcus diagnosis using the MGG-staining method was significantly higher than that using the ink-staining method. These results are important for diagnosing CM.

3D inpatient dose reconstruction from the PET-CT imaging of 90Y microspheres for metastatic cancer to the liver: feasibility study

PURPOSE

The introduction of radioembolization with microspheres represents a significant step forward in the treatment of patients with metastatic disease to the liver. This technique uses semiempirical formulae based on body surface area or liver and target volumes to calculate the required total activity for a given patient. However, this treatment modality lacks extremely important information, which is the three-dimensional (3D) dose delivered by microspheres to different organs after their administration. The absence of this information dramatically limits the clinical efficacy of this modality, specifically the predictive power of the treatment. Therefore, the aim of this study is to develop a 3D dose calculation technique that is based on the PET imaging of the infused microspheres.

METHODS

The Fluka Monte Carlo code was used to calculate the voxel dose kernel for 90Y source with voxel size equal to that of the PET scan. The measured PET activity distribution was converted to total activity distribution for the subsequent convolution with the voxel dose kernel to obtain the 3D dose distribution. In addition, dose-volume histograms were generated to analyze the dose to the tumor and critical structures.

RESULTS

The 3D inpatient dose distribution can be reconstructed from the PET data of a patient scanned after the infusion of microspheres. A total of seven patients have been analyzed so far using the proposed reconstruction method. Four patients underwent treatment with SIR-Spheres for liver metastases from colorectal cancer and three patients were treated with Therasphere for hepatocellular cancer. A total of 14 target tumors were contoured on post-treatment PET-CT scans for dosimetric evaluation. Mean prescription activity was 1.7 GBq (range: 0.58-3.8 GBq). The resulting mean maximum measured dose to targets was 167 Gy (range: 71-311 Gy). Mean minimum dose to 70% of target (D70) was 68 Gy (range: 25-155 Gy). Mean minimum dose to 90% of target (D90) was 53 Gy (range: 13-125 Gy).

CONCLUSIONS

A three-dimensional inpatient dose reconstruction method has been developed that is based on the PET/CT data of a patient treated with 90Y microspheres. It allows for a complete description of the absorbed dose by the tumor and critical structures. It represents the first step in building predictive models for treatment outcomes for patients receiving this therapeutic modality as well as it allows for better analysis of patients' dose response and will ultimately improve future treatment administration.

Aligned nano-porous microwave exfoliated graphite oxide ionic actuators with high strain and elastic energy density

A high-density aligned nanoporous activated microwave exfoliated graphite oxide (aMEGO) ionic actuator is studied. Before applying an external electric field, the cations and anions are randomly distributed in the composite. After applying the electric field, ions ingress in between the aligned aMEGO sheets through the nanopores to compensate the charges on the electrodes, resulting in the separation of neighboring sheets and unidirectional electro actuation.

Molecular characteristics of the MHC-DRA genes from yak (Bos grunniens) and Chinese yakow (Bos grunniens × Bos taurus)

Two full-length cDNAs (762 bp) of the DRA gene from yak and Chinese yakow were isolated and analysed to identify structural and functional variations. The sequences for DRA in yak (Bogr-DRA) and Chinese yakow (Bogr × BoLA-DRA) were essentially identical to those for cattle (99%) and buffalo (97%). Except for two substitutions in the amino acids comprising the domain for signal peptide (SP) in yak, the additional residues were highly conserved across the species investigated. Peptide-binding site (PBS) of Bogr-DRA and Bogr × BoLA-DRA was highly reserved in the α1 domain among all species investigated. The lack of mutation in Bogr-DRA is consistent with the conception that the gene is highly conserved among all mammalian species. The very high conservation of the DRA gene among ruminants, including yak, may be due to its recent evolutionary detachment.

Standardization and cross validation of alloreactive IFNγ ELISPOT assays within the clinical trials in organ transplantation consortium

Emerging evidence indicates memory donor-reactive T cells are detrimental to transplant outcome and that quantifying the frequency of IFNγ-producing, donor-reactive PBMCs by ELISPOT has potential utility as an immune monitoring tool. Nonetheless, differences in assay performance among laboratories limit the ability to compare results. In an effort to standardize assays, we prepared a panel of common cellular reagent standards, developed and cross validated a standard operating procedure (SOP) for alloreactive IFNγ ELISPOT assays in several research laboratories supported by the NIH-funded Clinical Trials in Organ Transplantation (CTOT) Consortium. We demonstrate that strict adherence to the SOP and centralized data analysis results in high reproducibility with a coefficient of variance (CV) of ≈ 30%. This standardization of IFNγ ELISPOT assay will facilitate interpretation of data from multicenter transplantation research studies and provide the foundation for developing clinical laboratory testing strategies to guide therapeutic decision-making in transplant patients.

Kidney transplantation from donors after brain or cardiac death in China--a clinical analysis of 94 cases

BACKGROUND

We analyzed outcomes of kidney transplantation (KTx) from donation after brain death (DBD) or cardiac death (DCD) in China under the current level of the health care system.

METHODS

Among 94 KTx performed from February 2007 to March 2012 in two organ transplant centers in the south of China, 50 KTx were used DBD and 44 DCD donors. We retrospectively analyzed the clinical outcomes.

RESULTS

At a mean follow-up of 25.5 months, the 1-year and 2-year graft survival rates were 96.8% and 95.2% respectively. Delayed graft function (DGF) occurred in 27.7% recipients, three of whom lost graft function. Among six observed acute rejection episodes, five were reversed. When compared to the DCD group in DBD patients were apt to recover from DGF. Serum creatinine decreased more promptly in the DBD than in DCD group. Serum creatinine in the DCD group increased after months 12, when it was significantly higher than that in the DBD group (P < .05).

CONCLUSIONS

Kidney transplantation from DBD donors showed good outcomes with few complications. Although KTx from DCD donors showed a higher DGF rate and longer duration of graft recovery, we achieved favorable short-term clinical outcome using this source.

Micronutrients-incorporated calcium phosphate particles with protective effect on osteoporotic bone tissue

BACKGROUND

Supplementation of individual micronutrient is inadequate for maintaining bone function because single micronutrient can not contribute significantly a positive remodeling balance.

OBJECTIVE

We developed the highly integrated, stably dietary multi-micronutrients with good bioavailability and low adverse effect on the improvement of bone consolidation in osteoporosis.

METHODS

The trace element-codoped calcium phosphate (teCaP) particles were prepared in the modified body fluid and carefully evaluated. Rats, aged 3 months, were ovariectomized and when 6 month intervened with the conditioned, low, moderate, and high teCaP diets.

RESULTS

The teCaP particles showed highly dissolvable in stomach juice-mimicing acidic solutions. Three months after intervention, the body weight increase showed remarkable differences among the low teCaP diet (~52 g), moderate teCaP diet (~34 g) and high teCaP diet (~23 g) group. In particular, the intake of moderate teCaP greatly improved the retention of trace elements in femural bone for better protection against the skeletal weakening, and resulted in a significant increase of bone mineral density (104.06%) in comparison with the conventional high calcium plus vitamin D3 diet (Control group).

CONCLUSIONS

These investigations improve our understanding of micronutrient retention on bone consolidation in osteoporotic bone tissue, and also provide new mild wet-chemical approach to prepare potent nutritionally effective edible complements to synergistically relieve bone degeneration and prevent osteoporosis.

Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study

AIM

The aim of the study was to analyse the prevalence and characteristics of secondary diabetes induced by 5-fluorouracil (5-FU) based chemotherapy in non-diabetic patients with colorectal cancer (CRC).

METHOD

A total of 422 consecutive CRC patients who received 5-FU-based chemotherapy were retrospectively analysed. Fasting plasma glucose (FPG) levels were determined before each cycle of chemotherapy during active treatment and regular follow-up. The prevalence and characteristics of secondary hyperglycaemia were investigated, with special focus on the clinical outcome.

RESULTS

Among the 422 CRC patients, 60 had pre-existing hyperglycaemia. In the remaining 362 with normal FPG levels before chemotherapy, 42 (11.6%) and 41 (11.3%) patients developed diabetes and impaired fasting glucose during the study period. Among the 42 secondary diabetic patients, 22 (52.4%) received anti-diabetes drug therapy, in 7 (16.7%) cases the FPG level returned to normal without any active intervention, and 13 (30.9%) cases received diet control and physiotherapy. Thirty-one (8.6%) patients developed diabetes. Based on the Common Terminology Criteria for Adverse Events, an adverse event over Grade 3 occurred in seven cases during follow-up. Diabetes-related adverse events had a serious negative impact on chemotherapy in six cases. Diabetes-related death occurred in three patients.

CONCLUSIONS

Secondary diabetes associated with 5-FU-based chemotherapy occurs in around 10% of CRC patients, with a significant negative impact on treatment and clinical outcome. 5-FU-related diabetes should be regarded as a common side effect of 5-FU treatment.

TU-E-BRB-06: Best in Physics (Therapy) - Development and Experimental Validation of EPID-Based 4D Dose Reconstruction

PURPOSE

To develop and validate an EPID-based 4D patient dose reconstruction framework accounting for linac delivery uncertainties, interfractional and intrafractional motions, and interplay effect.

METHODS

Patients with fiducial markers were scanned with 4D-CT for SBRT planning. Before treatment, in-room 4D-CT was performed. Both the MLC and the tumor movements were tracked by continuously acquiring EPID images during treatment. Instead of directly using the heterogeneous transit photon fluence measured by the EPID, this method reconstructed the incident beam fluence based on the MLC apertures measured by the EPID and the delivered MU recorded by the linac. To account for the time-dependent-geometry, the incident fluence distributions were sorted into their corresponding phases based on the tumor motion pattern detected by the EPID and accumulated as the incident fluence map for each phase. Together with 4D-CT, it was then used for Monte Carlo dose calculation. Deformable registration was performed to sum up the phase doses for treatment assessment. The feasibility of using the transit EPID images for incident fluence reconstruction was evaluated against EPID in-air measurements. The accuracy of 3D- and 4D-dose reconstruction was validated by a motordriven cylindrical diode array for six clinical SBRT plans.

RESULTS

The average difference between the measured and reconstructed fluence maps is within 0.16%. The reconstructed 3D-dose shows 1.4% agreement in the CAX-dose and >98.5% gamma-passing-rate (2%/2mm) in the peripheral-dose. A distorted dose distribution is observed in the measurement for the moving ArcCheck-phantom. The comparison between the measured and the reconstructed 4D-dose without considering interplay fails the gammaevaluation (59%-88.9% gamma-passing-rate). In contrast, when the interplay is considered, the dose distortion phenomena is successfully represented in the reconstructed dose (>97.6% gamma-passing-rate).

CONCLUSIONS

The experimental validation demonstrates that the proposed method provides a practical way to reconstruct the fractional 4D-doses received by the patient and enables adaptive SBRT strategy.

SU-E-J-139: Feasibility of Using EPID for Real-Time Target Localization during Treatment

PURPOSE

This study aims to investigate the feasibility of using the images of the treatment fields acquired by an electronic portal imaging device (EPID) for real-time target localization.

METHODS

Forty one patients treated with IMRT and RapidArc were recruited in this study including 37 prostate patients and 4 lung patients. These patients were grouped as: prostate IMRT with lymph node (n=14), prostate IMRT without lymph node (n=17), prostate RapidArc (n=6), and lung IMRT (n=4). For each patient, two to four fiducial markers were implanted inside the tumor. The DRR, which projects the patient anatomy and the fiducial marker at the EPID location, was reconstructed for each field. The MLC aperture of each control point was overlay on its corresponding DRR to evaluate the fractional time when the fiducial marker was seen on the EPID image. The probability of seeing at least one, two, three, and four fiducial markers during the treatment was recorded.

RESULTS

For the prostate IMRT patients without lymph nodes included in the target volume, the average probability of seeing at least one, two, three, and four fiducial markers during the treatment was 50% (35%-59%), 39% (23%-51%), 24% (7%-38%), and 12% (4%-29%), respectively. For the prostate IMRT patients with lymph nodes, the probability was 41% (24%-51%), 29% (12%-42%), 15% (3%-24%), and 7% (4%-15%), respectively. For prostate RapidArc treatments using two arcs, the average probability of seeing at least one fiducial marker was 81% (58%-90%) for the full arc and 74% (53%-94%) for the partial arc. For the lung IMRT treatment, the average probability of seeing at least one fiducial marker was 34% (20%-52%).

CONCLUSIONS

The continuous image acquisition from the EPID during the treatment provides sufficient target movement information for real-time target localization and intrafractional target motion correction for advanced radiotherapy treatments.